Akums Drugs Secures 20-Year Patent for Dual-Release PPI Technology Targeting GERD Treatment
核心洞察
Akums Drugs and Pharmaceuticals Limited received a 20-year patent for its "Dual Release Gastro-Resistant Composition (搜索)" technology, granted on October 31, 2025, by the Indian Patent Office.
The patented formulation represents a next-generation proton pump inhibitor (搜索) therapy designed for moderate to severe or treatment-resistant gastroesophageal reflux disease (搜索) affecting 784 million people globally.
The innovative dual-release system delivers medication in two phases, with 50% released in the duodenum and 50% in the ileum, providing extended drug absorption and prolonged therapeutic action.
Akums Drugs and Pharmaceuticals Limited has secured a significant 20-year patent for its innovative dual-release proton pump inhibitor (搜索) technology, marking a potential breakthrough in gastroesophageal reflux disease (搜索) (GERD (搜索)) treatment. The patent, numbered 573119, was granted on October 31, 2025, by the Patent Office of the Government of India for the "Dual Release Gastro-Resistant Composition (搜索)."
Addressing a Global Health Challenge
GERD (搜索) represents one of the most prevalent digestive disorders worldwide, affecting nearly 14% of the global population. According to the company's data, an estimated 784 million people lived with the condition as of 2019. In India specifically, recent meta-analyses estimate a pooled prevalence of 15.6%, highlighting the substantial patient population that could benefit from improved therapeutic options.
The condition occurs when stomach acid repeatedly flows back into the esophagus, leading to heartburn and discomfort. While conventional proton pump inhibitors such as Pantoprazole and Esomeprazole are commonly used to reduce stomach acid and promote healing of acid-related damage, these treatments face significant limitations in providing sustained relief.
Innovative Dual-Phase Release Technology
Akums' patented formulation addresses the shortcomings of conventional PPIs through its unique dual-release mechanism. The technology releases medication in two distinct phases: 50% in the duodenum and 50% in the ileum. This staged delivery system enables extended drug absorption and prolonged duration of action, addressing the common problem of nocturnal acid breakthrough and incomplete symptom relief associated with traditional PPI (搜索) therapies.
The company's dual-release gastro-resistant tablet has been specifically designed to provide "better heartburn free days (daytime or night time), long-lasting heartburn relief, improved compliance, and enhanced quality of life with just one tablet a day," according to the patent filing.
Advanced Manufacturing Technology
The formulation employs what Akums describes as "tablet-in-tablet technology," which ensures better stability, uniform drug release, and improved formulation attributes. This manufacturing approach represents a significant advancement in pharmaceutical delivery systems, potentially setting new standards for extended-release acid suppression therapy.
Regulatory Approval and Market Position
The advanced, once-daily formulation has already received approval from India's Drug Controller General of India (搜索) (DCGI (搜索)), positioning Akums to commercialize this technology in the Indian market. The company emphasized that this development "reinforces Akums' commitment to developing innovative and patient-friendly therapies for chronic acid-related disorders."
The patent term extends for 20 years from November 19, 2022, providing Akums with substantial market exclusivity for this technology. This intellectual property protection could prove valuable given the large patient population affected by moderate to severe or treatment-resistant GERD (搜索) who may benefit from improved therapeutic options that address the limitations of current PPI (搜索) treatments.